Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients

Inclusion Criteria:

• Signed Written Informed Consent
• Age≥ 17 and <80 years,
• Newly diagnosed T2DM (defined as T2DM diagnosed within 6 months prior to enrollment)
• Oral antidiabetic agents naïve (defined as without receiving any anti-diabetic medication therapy before, or having received anti-diabetic medication ≤ 14 days but not received any antidiabetic medication within the last 1 month prior to enrollment)
• HbA1c ≥ 7.0% and ≤10.0%

Exclusion Criteria:

• WOCBP
• BMI≥35 Kg/m2 or BMI <18.5 Kg/m2
• HbA1c>10.0% or <7.0%
• Active liver disease and/or significant abnormal liver function
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
• Congestive heart failure defined as New York Heart Association (NYHA) class III or IV and /or left ventricular ejection fraction ≤40%
• Significant cardiovascular history with the past 6 months
• Severe retinopathy, persistent uncontrolled hypertension (SBP≥180mmHg, or DBP≥105mmHg)
• Severe chronic gastrointestinal disease
• History of alcohol abuse or illegal drug abuse within the past 12 months
• Diagnosed anemia
• Creatine kinase ≥3 X ULN
• Serum creatinine ≥1.5 mg/dL(133μmol/L) [males], ≥1.4 mg/dL(124 μmol/L)[females]
• ALT and/or AST > 1.5 X ULN and/or total bilirubin > 2 X ULN
• Hemoglobin <12g/dL [males], <11g/dL [females]
• Allergies and Adverse Drug Reactions
• Prohibited Treatments and/or Therapies
• Prisoners or subjects who are involuntarily incarcerated
• Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
• Subjects decline to participate